Dazukibart is effective in reducing disease activity in adults with refractory dermatomyositis
1. CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2. Treatment-related ...
Tag: immunotherapy
Neoadjuvant Nivolumab/Ipilimumab Vs Chemotherapy in Resectable NSCLC
1. Median event-free survival was 54.8 months with immunotherapy vs 20.9 months with chemotherapy, with HR 0.77 (non-significant). 2. Grade ...
AstraZeneca’s Imfinzi shows positive results in phase 3 trial for treatment of limited-stage small cell lung cancer
1. Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. ...
Pembrolizumab with radiotherapy and surgery improves survival in high-risk soft tissue sarcoma
1. Pembrolizumab plus radiotherapy and surgery significantly improved disease-free survival. 2. Grade 3 or higher adverse events were more common ...
Cadonilimab plus chemotherapy improves survival in recurrent or metastatic cervical cancer
1. Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with persistent, recurrent, or metastatic cervical cancer. 2. Common grade ...
2 Minute Medicine Rewind November 25, 2024
Estimated Effectiveness of Influenza Vaccines in Preventing Secondary Infections in Households 1. Influenza vaccination was associated with a reduced risk ...
Nivolumab does not improve survival in patients with advanced renal cell carcinoma with progression after immune checkpoint inhibitors
1. No significant difference was seen regarding progression-free survival between the tivozanib-nivolumab and tivozanib monotherapy groups. 2. Serious adverse events ...
Perioperative pembrolizumab improves survival in resectable early-stage non-small cell lung cancer
1. 36-month overall survival and median event-free survival were significantly greater in the pembrolizumab group compared to control. 2. Grade ...
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors
1. Treatment of desmoid tumours with dual anti-CTLA-4 and anti-PD-1 blockade with ipilimumab and nivolumab resulted in an overall response ...
Adaptimmune’s Afami-cel is the first FDA-approved T-cell receptor therapy for synovial sarcoma
Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated an overall response rate of ...